| abstract |
Disclosed is a novel LXRβ agonist which is useful as an agent for prevention and/or treatment of artherosclerosis or the like. The LXRβ agonist is composed of a carbinol compound represented by general formula (I), a salt thereof, or a solvate of the compound or the salt. (In the formula, V and W each independently represents N or C-R 7 ; X and Y each independently represents CH 2 , C=O, SO 2 or the like; Z represents CH or N; R 1 , R 2 and R 7 each independently represents a hydrogen atom, a C 1-8 alkyl group or the like; R 3 represents a C 1-8 alkyl group; R 4 represents an optionally substituted C 6-10 aryl group or an optionally substituted 5-11 membered heterocyclic group; R 5 and R 6 each represents a hydrogen atom or the like; L represents a C 1-8 alkyl chain which may be substituted with an oxo group, or the like; and n represents an integer of 0-2.) |